EU Biotech Act clause could cost health systems €70m per medicine, Commission warns

Quick summary

The EU Commission estimates a single clause in its proposed Biotech Act could cost public health systems €70 million per medicine by delaying generic competition. Extended data protection periods would push back when cheaper alternatives can enter the market, intensifying cost pressures on already strained national health budgets.

Why it matters

If the Biotech Act passes with this provision, patients and health systems across the EU will face delayed access to affordable generic medicines, directly raising treatment costs at a time when healthcare budgets are under strain. The €70 million figure per drug suggests the financial impact could be substantial across multiple medicines, affecting medication availability and affordability in your country's health system.

Key takeaways

• ›The Commission's own analysis estimates €70 million in costs per medicine from the data protection extension clause.
• ›The clause would delay when generic versions can enter the market and compete on price.
• ›Health economists and patient groups have warned that extended exclusivity periods inflate costs for fiscally pressured national health systems.
• ›The Biotech Act will move through European Parliament, though no parliamentary vote date has been set.